Talk:Atomoxetine

Atomoxetine (also known by the brand name Strattera) is a prescription substance of the phenylpropylamine class. It acts as a selective norepinephrine reuptake inhibitor (sNRI), and is used in the treatment of attention-deficit hyperactivity disorder (ADHD).

Unlike stimulant medications such as methylphenidate or amphetamine, atomoxetine is classified as a non-stimulant therapeutic agent with a low abuse potential. It exerts its effects by increasing extracellular levels of norepinephrine, particularly within the prefrontal cortex. Recent research suggests that atomoxetine also mildy inhibits the reuptake of serotonin at clinical dosages as well.

Atomoxetine is a synthetic molecule of the phenylpropylamine and phenoxyphenylpropylamine chemical classes. It features a substituted phenyl ring attached to a propylamine chain, which is further connected to a phenoxy group.

Atomoxetine blocks the norepinephrine transporter (NET), leading to increased norepinephrine availability, especially in the prefrontal cortex — an area associated with attention and executive functioning.

Unlike stimulants, atomoxetine does not significantly affect dopamine concentrations in the striatum or nucleus accumbens, which contributes to its lack of reinforcing or euphoric properties.

Atomoxetine does not produce traditional stimulant or euphoric effects and is not considered recreational. However, at therapeutic doses, it may produce the following effects:

• Increased focus
• Enhanced attention span
• Reduced impulsivity
• Emotional blunting (occasionally reported)
• Subtle mood stabilization

Template:Warningbox

• SSRIs / SNRIs: May increase atomoxetine levels and the risk of Serotonin syndrome. This may include symptoms such as agitation, confusion, and cardiovascular abnormalities.
• MAOIs: Contraindicated. Combining with monoamine oxidase inhibitors can cause hypertensive crises. A 14-day washout period is required.
• Cannabis / CBD: Cannabinoids may increase serum levels of atomoxetine, enhancing side effects like nausea, anxiety, and mood swings.
• Amphetamines: Increases the risk of cardiac side effects, including arrhythmias, particularly in individuals with preexisting cardiovascular conditions or electrolyte imbalances.
• Phenidates: Increases the risk of cardiac side effects, including arrhythmias, particularly in individuals with preexisting cardiovascular conditions or electrolyte imbalances.

Atomoxetine is generally considered to have low toxicity when used as prescribed. However, it can produce adverse effects, especially in sensitive individuals.

Common adverse effects

• Nausea
• Headache
• Insomnia or drowsiness
• Appetite suppression
• Dizziness
• Dry mouth

Serious risks

• Suicidal ideation (particularly in adolescents)
• Liver damage (rare)
• Increased blood pressure or heart rate
• Mood swings or aggression
• Priapism

Close monitoring is recommended during the initial weeks of treatment, particularly in children and adolescents.

Atomoxetine does not produce tolerance, cravings, or physical dependence. It is not habit-forming and is not classified as a controlled substance in most jurisdictions.

• United States: Prescription-only; not scheduled.
• Canada: Prescription-only.
• Australia: Prescription-only.
• Brazil: Marketed as Atentah.
• European Union: Prescription-only. Sold under various brand names including Strattera, Mylan, and Auroxetyn depending on the country.

• Methylphenidate
• Amphetamine
• Norepinephrine

•   Atomoxetine (Wikipedia)
• Template:PubChem
• Template:DrugBank